ClinicalTrials.gg
CompletedNCT02197247Updated Jul 12, 2021Results posted

Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC

A Phase 1 interventional study of Pharmacokinetic sampling - AZD9291 and Rifampicin in Non Small Cell Lung Cancer, sponsored by AstraZeneca. Completed at 18 sites in 6 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-07-12.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
56th of 90
41 · median 51
Started
2014
with 9 others
Phase 1
18 of 90
1 open now
Registered
7th of 90
by date
Lead sponsor
29 of 90
AstraZeneca

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 56th largest by enrollment, is one of 10 that started in 2014, is one of 18 in phase 1, and was the 7th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior therapy with an approved EGFR tyrosine kinase inhibitor (TKI) agent.

Part A will assess the effect of rifampicin on the pharmacokinetic (PK) parameters of AZD9291 and metabolites AZ5104 and AZ7550 following multiple oral dosing of both rifampicin and AZD9291 in a fasted state.

Part B will allow patients further access to AZD9291 after the PK phase (Part A) and will provide for additional safety data collection. All patients who complete Part A will be able to enter part B, and continue to receive AZD9291 80 mg once daily until: disease progression; they are no longer deriving clinical benefit; or any other reason.

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • oncology, cancer, non small cell lung cancer, anticancer drug, pharmacokinetics, AZD9291, rifampicin, CYP P450 inducer, EGFR genes
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

For inclusion in the study patient should fulfil the following criteria:

  1. Male or female, aged at least 18 years. 2. Histological or cytological confirmation diagnosis of NSCLC. 3. Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI, eg gefitinib, erlotinib or afatinib. In addition, other may have been given. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.
  1. Confirmation that the tumour harbours an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).
  1. (ECOG) performance status 0-1 with no deterioration over the previous 2 weeks (Appendix G).
  1. Patients must have a of ≥12 weeks as estimated at the time of screening.
  1. Females should be using adequate measures and must have a negative pregnancy test prior to start of dosing if of , or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening: defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments. Women under 50 years old would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution. Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not tubal ligation.
  1. Male patients should be willing to use barrier contraception, ie, condoms, until 6 months after last study drug is taken.
  1. Contact lens wearers must be prepared to not wear contact lenses and wear glasses for the duration of the rifampicin dosing.
  1. Participation in another clinical study with an IP during the last 14 days (or a longer period depending on the defined characteristics of the agents used).
  2. Treatment with any of the following: Treatment with an EGFR TKI (eg, erlotinib or gefitinib) w/in 8 days or approx. 5 x half-life, whichever is the longer, of the first dose of study treatment; any cytotoxic chemo, agents or other anticancer drugs from a previous treatment regimen w/in 14 days of the first dose of study treatment; major surgery (excluding placement of vascular access) w/in 4 weeks of the first dose of study treatment; radiotherapy with a limited field of radiation for palliation w/in 1 week of the first dose of study treatment, with the exception of patients receiving radiation to more than 30% of bone marrow or with a wide field of radiation which must be completed w/in 4 weeks of the first; patients currently receiving (or unable to stop use prior to receiving the first dose) medications or herbal supplements known to be potent inhibitors of (at least 1 week prior) and potent inducers of CYP3A4 (at least 3 week prior). All patients must avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer/inhibitory effects on CYP3A4.
  3. Any unresolved toxicities from prior therapy greater than Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.
  4. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the first administration of the IP until the final PK sample collection on Day 78 of Part A.
  5. Spinal cord compression or unless asymptomatic, stable and not requiring for at least 4 weeks prior to start of study treatment.
  6. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the Investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardise compliance with the protocol, or active infection including , and . Screening for chronic conditions is not required.
  7. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: ANC \<1.5 x 10\^9/L; count \<100 x 10\^9/L; \<90 g/L; >2.5 times the if no demonstrable liver or >5 times ULN in the presence of liver metastases; AST >2.5 times ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases; Total >1.5 times ULN if no liver metastases or >3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases; creatinine >1.5 times ULN concurrent with \<50 ml/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is >1.5 times ULN.
  8. Any of the following cardiac criteria: Mean resting interval corrected for heart rate using Fridericia's correction factor (QTcF) >470 msec obtained from 3 (ECGs); any abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, third degree heart block, second degree heart block, PR interval >250 msec; any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval.
  9. Patients unable to swallow oral medication or patients with GI disorders or significant GI resection likely to interfere with the absorption of AZD9291.
  10. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
  11. Women who are breastfeeding.
  12. Patients with a known to AZD9291 or rifampicin or any of the of the products.
  13. Concomitant medication for use with rifampicin (including, but not limited to): cisapride, oral midazolam, nisoldipine, pimozide, quinidine, dofetilide, triazolam, levacetylmethadol (levomethadyl), 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA)-reductase inhibitors metabolised by CYP3A4, such as lovastatin and simvastatin, ergot alkaloids metabolised by CYP3A4, such as dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine).
  14. For optional genetic research: .Previous allogenic bone marrow transplant or Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Rifampicin and AZD9291

    Sequential treatments of AZD9291 alone followed by AZD9291 +rifampicin, followed by AZD9291 alone.

    Procedure: Pharmacokinetic sampling - AZD9291 · Drug: Rifampicin · Drug: AZD9291 tablet dosing · Procedure: Pharmacokinetic sampling - rifampicin · Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550

Interventions

  • ProcedurePharmacokinetic sampling - AZD9291

    Blood sampling to measure AZD9291

  • Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)

  • Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.

  • ProcedurePharmacokinetic sampling - rifampicin

    Blood sampling to measure rifampicin levels

  • ProcedurePharmacokinetic sampling - AZ5140 and AZ7550

    Blood samples to measure levels of AZ5140 and AZ7550

06

What researchers measure

Primary outcomes

  1. Assessment of Maximum Plasma Concentration for AZD9291 After Dosing Alone and in Combination With Rifampicin (Css,Max)

    Rate and extent of absorption of AZD9291 by assessment of maximum plasma concentration at steady state (Css,max). AZD9291 doses were first without, then with rifampicin (Periods 1 and 2, respectively).

    Time frame: Samples collected on Day 28 following AZD9291 alone and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  2. Assessment of Area Under the Plasma Concentration-time Curve During the Dosing Interval for AZD9291 After Dosing Alone and in Combination With Rifampicin (AUCtau)

    Rate and extent of absorption of AZD9291 by assessment of AUCtau. AZD9291 doses were first without, then with rifampicin (Periods 1 and 2, respectively).

    Time frame: Samples collected on Day 28 following AZD9291 alone and Day 49 following AZD9291 and rifampicin at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

Secondary outcomes

  1. Assessment of Css,Max for AZD9291 Before and After Rifampicin

    Rate and extent of absorption of AZD9291 by assessment of Css,max. AZD9291 alone before rifampicin (Period 1) and AZD9291 alone after rifampicin (Period 3).

    Time frame: Samples collected on Day 28 and 77 following AZD9291 alone at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  2. Assessment of Css,Max for AZ5104 (Metabolite)

    Rate and extent of absorption of AZ5104 (metabolite) by assessment of Css,max. AZD9291 dosing alone and in combination with rifampicin (all periods).

    Time frame: Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  3. Assessment of Css,Max for AZ7550 (Metabolite)

    Rate and extent of absorption of AZ7550 (metabolite) by assessment of Css,max. AZD9291 dosing alone and in combination with rifampicin (all periods).

    Time frame: Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  4. Assessment of Css,Max for Rifampicin

    Rate and extent of absorption of rifampicin by assessment of Css,max. AZD9291 dosing in combination with rifampicin (Period 2).

    Time frame: Samples collected on Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  5. Assessment of AUCtau for AZD9291 Before and After Rifampicin

    Rate and extent of absorption of AZD9291 by assessment of AUCtau. AZD9291 alone before rifampicin (Period 1) and AZD9291 alone after rifampicin (Period 3).

    Time frame: Samples collected on Day 28 and 77 following AZD9291 alone at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  6. Assessment of AUCtau for AZ5104 (Metabolite)

    Rate and extent of absorption of AZ5104 (metabolite) by assessment of AUCtau. AZD9291 dosing alone and in combination with rifampicin (all periods).

    Time frame: Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  7. Assessment of AUCtau for AZ7550 (Metabolite)

    Rate and extent of absorption of AZ7550 (metabolite) by assessment of AUCtau. AZD9291 dosing alone and in combination with rifampicin (all periods).

    Time frame: Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  8. Assessment of AUCtau for Rifampicin

    Rate and extent of absorption of rifampicin by assessment of AUCtau. AZD9291 dosing in combination with rifampicin (Period 2).

    Time frame: Samples collected on Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  9. Assessment of Tss,Max for AZD9291, and AZ5104 and AZ7550 (Metabolites)

    Rate and extent of absorption of AZD9291, and AZ5104 and AZ7550 (metabolites) by assessment of time to reach maximum plasma concentration at steady state (tss,max). AZD9291 dosing alone and in combination with rifampicin (all periods).

    Time frame: Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  10. Assessment of Tss,Max for Rifampicin

    Rate and extent of absorption of rifampicin by assessment of tss,max. AZD9291 dosing in combination with rifampicin (Period 2).

    Time frame: Samples collected on Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  11. Assessment of Css,Min for AZD9291, and AZ5104 and AZ7550 (Metabolites)

    Rate and extent of absorption of AZD9291, and AZ5104 and AZ7550 (metabolites) by assessment of minimum plasma concentration at steady state (Css,min). AZD9291 dosing alone and in combination with rifampicin (all periods).

    Time frame: Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  12. Assessment of Css,Min for Rifampicin

    Rate and extent of absorption of rifampicin by assessment of minimum plasma concentration at steady state (Css,min). AZD9291 dosing in combination with rifampicin (Period 2).

    Time frame: Samples collected on Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  13. Assessment of CLss/F for AZD9291

    Rate and extent of absorption of AZD9291 by assessment of the apparent plasma clearance following oral administration and multiple dosing (CLss/F). AZD9291 dosing alone and in combination with rifampicin (all periods).

    Time frame: Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  14. Assessment of CLss/F for Rifampicin

    Rate and extent of absorption of rifampicin by assessment of CLss/F. AZD9291 dosing in combination with rifampicin (Period 2).

    Time frame: Samples collected on Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  15. Assessment of the Metabolic Ratios of Css,Max for AZ5104 and AZ7550 (MRCss,Max)

    Assessment of the metabolite to parent ratio (calculated as AZ5104 to AZD9291 and AZ7550 to AZD9291) for Css,max (MRCss,max). AZD9291 dosing alone and in combination with rifampicin (all periods).

    Time frame: Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

  16. Assessment of the Metabolic Ratios of AUCtau for AZ5104 and AZ7550 (MRAUCtau)

    Assessment of the metabolite to parent ratio (calculated as AZ5104 to AZD9291 and AZ7550 to AZD9291) for AUCtau (MRAUCtau). AZD9291 dosing alone and in combination with rifampicin (all periods).

    Time frame: Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.

07

Results

Posted Sep 28, 2016
Limitations and caveats
At end of Part B, the CAP allowed patients to continue receiving AZD9291 if still deriving clinical benefit. No clinical data was databased during the CAP; thus AE data is presented to end of Part B only.

Participant flow

First patient enrolled: 04 December 2014; Last Subject Last Visit Part A: 09 July 2015 and Part B: 29 June 2016. Study performed at 18 sites across Asia, North America and Western Europe. Part A assessed effect of multiple doses of rifampicin on PK of AZD9291; Part B allowed subjects further access to AZD9291 and provided additional safety data.

Part A: Day 1-28 (AZD9291 Alone)
Participant flow — Part A: Day 1-28 (AZD9291 Alone)
MilestoneAZD9291 and Rifampicin (Part A); AZD9291 Alone (Part B)
Started41
Completed41
Not completed0
Part A: Day 29-49 (AZD9291+Rifampicin)
Participant flow — Part A: Day 29-49 (AZD9291+Rifampicin)
MilestoneAZD9291 and Rifampicin (Part A); AZD9291 Alone (Part B)
Started41
Completed37
Not completed4
Withdrew: Adverse event2
Withdrew: Condition under investigation worsened2
Part A: Day 50-77 (AZD9291 Alone)
Participant flow — Part A: Day 50-77 (AZD9291 Alone)
MilestoneAZD9291 and Rifampicin (Part A); AZD9291 Alone (Part B)
Started37
Completed32
Not completed5
Withdrew: Condition under investigation worsened5
Part B: Day 78 to End Part B (AZD9291)
Participant flow — Part B: Day 78 to End Part B (AZD9291)
MilestoneAZD9291 and Rifampicin (Part A); AZD9291 Alone (Part B)
Started34
Completed19
Not completed15
Withdrew: Adverse event2
Withdrew: Withdrawal by subject2
Withdrew: Newly discovered brain metastases1
Withdrew: Death1
Withdrew: Condition under investigation worsened9

Outcome measures

PrimaryAssessment of Maximum Plasma Concentration for AZD9291 After Dosing Alone and in Combination With Rifampicin (Css,Max)

Rate and extent of absorption of AZD9291 by assessment of maximum plasma concentration at steady state (Css,max). AZD9291 doses were first without, then with rifampicin (Periods 1 and 2, respectively).

Time frame:
Samples collected on Day 28 following AZD9291 alone and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · nanomolar (nM)
Assessment of Maximum Plasma Concentration for AZD9291 After Dosing Alone and in Combination With Rifampicin (Css,Max)
nanomolar (nM)AZD9291 Alone (Period 1)AZD9291 + Rifampicin (Period 2)
Assessment of Maximum Plasma Concentration for AZD9291 After Dosing Alone and in Combination With Rifampicin (Css,Max)577.4 ± 44.7147.5 ± 48.2
Statistical analysis
  • AZD9291 Alone (Period 1) vs AZD9291 + Rifampicin (Period 2) · Geometric least-squares (ls) mean ratio: 27.16 · 90% CI 24.36 to 30.29AZD9291+rifampicin / AZD9291 alone (Period 2 versus Period 1).
PrimaryAssessment of Area Under the Plasma Concentration-time Curve During the Dosing Interval for AZD9291 After Dosing Alone and in Combination With Rifampicin (AUCtau)

Rate and extent of absorption of AZD9291 by assessment of AUCtau. AZD9291 doses were first without, then with rifampicin (Periods 1 and 2, respectively).

Time frame:
Samples collected on Day 28 following AZD9291 alone and Day 49 following AZD9291 and rifampicin at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · nM * hour (nM*h)
Assessment of Area Under the Plasma Concentration-time Curve During the Dosing Interval for AZD9291 After Dosing Alone and in Combination With Rifampicin (AUCtau)
nM * hour (nM*h)AZD9291 Alone (Period 1)AZD9291 + Rifampicin (Period 2)
Assessment of Area Under the Plasma Concentration-time Curve During the Dosing Interval for AZD9291 After Dosing Alone and in Combination With Rifampicin (AUCtau)10870 ± 44.32192 ± 43.8
Statistical analysis
  • AZD9291 Alone (Period 1) vs AZD9291 + Rifampicin (Period 2) · Geometric ls mean ratio: 21.55 · 90% CI 19.50 to 23.83AZD9291+rifampicin / AZD9291 alone (Period 2 versus Period 1).
SecondaryAssessment of Css,Max for AZD9291 Before and After Rifampicin

Rate and extent of absorption of AZD9291 by assessment of Css,max. AZD9291 alone before rifampicin (Period 1) and AZD9291 alone after rifampicin (Period 3).

Time frame:
Samples collected on Day 28 and 77 following AZD9291 alone at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · nM
Assessment of Css,Max for AZD9291 Before and After Rifampicin
nMAZD9291 Alone (Period 1)AZD9291 Alone (Period 3)
Assessment of Css,Max for AZD9291 Before and After Rifampicin577.4 ± 44.7531.4 ± 37.9
Statistical analysis
  • AZD9291 Alone (Period 1) vs AZD9291 Alone (Period 3) · Geometric ls mean ratio: 95.53 · 90% CI 85.27 to 107.03AZD9291 alone / AZD9291 alone (Period 3 versus Period 1). No pre-specified margins for equivalence test for AZD9291 alone in separate periods, but analysed for consistency with AZD9291+rifampicin / AZD9291 alone analysis (primary outcome measure).
SecondaryAssessment of Css,Max for AZ5104 (Metabolite)

Rate and extent of absorption of AZ5104 (metabolite) by assessment of Css,max. AZD9291 dosing alone and in combination with rifampicin (all periods).

Time frame:
Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · nM
Assessment of Css,Max for AZ5104 (Metabolite)
nMAZD9291 Alone (Period 1)AZD9291 + Rifampicin (Period 2)AZD9291 Alone (Period 3)
Assessment of Css,Max for AZ5104 (Metabolite)60.40 ± 57.212.28 ± 52.650.73 ± 49.8
Statistical analysis
  • AZD9291 Alone (Period 1) vs AZD9291 + Rifampicin (Period 2) · Geometric ls mean ratio: 21.72 · 90% CI 19.08 to 24.72AZD9291+rifampicin / AZD9291 alone (Period 2 versus Period 1). No pre-specified margins for equivalence test for metabolites, but analysed for consistency with AZD9291 analysis.
  • AZD9291 Alone (Period 1) vs AZD9291 Alone (Period 3) · Geometric ls mean ratio: 88.31 · 90% CI 77.17 to 101.07AZD9291 alone / AZD9291 alone (Period 3 versus Period 1). No pre-specified margins for equivalence test for metabolites, but analysed for consistency with AZD9291 analysis.
SecondaryAssessment of Css,Max for AZ7550 (Metabolite)

Rate and extent of absorption of AZ7550 (metabolite) by assessment of Css,max. AZD9291 dosing alone and in combination with rifampicin (all periods).

Time frame:
Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · nM
Assessment of Css,Max for AZ7550 (Metabolite)
nMAZD9291 Alone (Period 1)AZD9291 + Rifampicin (Period 2)AZD9291 Alone (Period 3)
Assessment of Css,Max for AZ7550 (Metabolite)53.54 ± 43.773.14 ± 25.053.24 ± 34.4
Statistical analysis
  • AZD9291 Alone (Period 1) vs AZD9291 + Rifampicin (Period 2) · Geometric ls mean ratio: 139.32 · 90% CI 127.74 to 151.96AZD9291+rifampicin / AZD9291 alone (Period 2 versus Period 1). No pre-specified margins for equivalence test for metabolites, but analysed for consistency with AZD9291 analysis.
  • AZD9291 Alone (Period 1) vs AZD9291 Alone (Period 3) · Geometric ls mean ratio: 100.75 · 90% CI 92.04 to 110.29AZD9291 alone / AZD9291 alone (Period 3 versus Period 1). No pre-specified margins for equivalence test for metabolites, but analysed for consistency with AZD9291 analysis.
SecondaryAssessment of Css,Max for Rifampicin

Rate and extent of absorption of rifampicin by assessment of Css,max. AZD9291 dosing in combination with rifampicin (Period 2).

Time frame:
Samples collected on Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · nanogram per millilitre (ng/mL)
Assessment of Css,Max for Rifampicin
nanogram per millilitre (ng/mL)AZD9291 + Rifampicin (Period 2)
Assessment of Css,Max for Rifampicin13810 ± 40.6
SecondaryAssessment of AUCtau for AZD9291 Before and After Rifampicin

Rate and extent of absorption of AZD9291 by assessment of AUCtau. AZD9291 alone before rifampicin (Period 1) and AZD9291 alone after rifampicin (Period 3).

Time frame:
Samples collected on Day 28 and 77 following AZD9291 alone at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · nM*h
Assessment of AUCtau for AZD9291 Before and After Rifampicin
nM*hAZD9291 Alone (Period 1)AZD9291 Alone (Period 3)
Assessment of AUCtau for AZD9291 Before and After Rifampicin10870 ± 44.310060 ± 36.8
Statistical analysis
  • AZD9291 Alone (Period 1) vs AZD9291 Alone (Period 3) · Geometric ls mean ratio: 95.89 · 90% CI 86.37 to 106.45AZD9291 alone / AZD9291 alone (Period 3 versus Period 1). No pre-specified margins for equivalence test for AZD9291 alone in separate periods, but analysed for consistency with AZD9291+rifampicin / AZD9291 alone analysis (primary outcome measure).
SecondaryAssessment of AUCtau for AZ5104 (Metabolite)

Rate and extent of absorption of AZ5104 (metabolite) by assessment of AUCtau. AZD9291 dosing alone and in combination with rifampicin (all periods).

Time frame:
Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · nM*h
Assessment of AUCtau for AZ5104 (Metabolite)
nM*hAZD9291 Alone (Period 1)AZD9291 + Rifampicin (Period 2)AZD9291 Alone (Period 3)
Assessment of AUCtau for AZ5104 (Metabolite)1206 ± 55.8210.3 ± 48.01029 ± 49.7
Statistical analysis
  • AZD9291 Alone (Period 1) vs AZD9291 + Rifampicin (Period 2) · Geometric ls mean ratio: 18.76 · 90% CI 16.61 to 21.19AZD9291+rifampicin / AZD9291 alone (Period 2 versus Period 1). No pre-specified margins for equivalence test for metabolites, but analysed for consistency with AZD9291 analysis.
  • AZD9291 Alone (Period 1) vs AZD9291 Alone (Period 3) · Geometric ls mean ratio: 90.08 · 90% CI 79.34 to 102.27AZD9291 alone / AZD9291 alone (Period 3 versus Period 1). No pre-specified margins for equivalence test for metabolites, but analysed for consistency with AZD9291 analysis.
SecondaryAssessment of AUCtau for AZ7550 (Metabolite)

Rate and extent of absorption of AZ7550 (metabolite) by assessment of AUCtau. AZD9291 dosing alone and in combination with rifampicin (all periods).

Time frame:
Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · nM*h
Assessment of AUCtau for AZ7550 (Metabolite)
nM*hAZD9291 Alone (Period 1)AZD9291 + Rifampicin (Period 2)AZD9291 Alone (Period 3)
Assessment of AUCtau for AZ7550 (Metabolite)1107 ± 41.71416 ± 25.61111 ± 31.7
Statistical analysis
  • AZD9291 Alone (Period 1) vs AZD9291 + Rifampicin (Period 2) · Geometric ls mean ratio: 129.81 · 90% CI 119.14 to 141.44AZD9291+rifampicin / AZD9291 alone (Period 2 versus Period 1). No pre-specified margins for equivalence test for metabolites, but analysed for consistency with AZD9291 analysis.
  • AZD9291 Alone (Period 1) vs AZD9291 Alone (Period 3) · Geometric ls mean ratio: 100.76 · 90% CI 92.15 to 110.19AZD9291 alone / AZD9291 alone (Period 3 versus Period 1). No pre-specified margins for equivalence test for metabolites, but analysed for consistency with AZD9291 analysis.
SecondaryAssessment of AUCtau for Rifampicin

Rate and extent of absorption of rifampicin by assessment of AUCtau. AZD9291 dosing in combination with rifampicin (Period 2).

Time frame:
Samples collected on Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · ng*h/mL
Assessment of AUCtau for Rifampicin
ng*h/mLAZD9291 + Rifampicin (Period 2)
Assessment of AUCtau for Rifampicin58610 ± 36.8
SecondaryAssessment of Tss,Max for AZD9291, and AZ5104 and AZ7550 (Metabolites)

Rate and extent of absorption of AZD9291, and AZ5104 and AZ7550 (metabolites) by assessment of time to reach maximum plasma concentration at steady state (tss,max). AZD9291 dosing alone and in combination with rifampicin (all periods).

Time frame:
Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Median · h
Assessment of Tss,Max for AZD9291, and AZ5104 and AZ7550 (Metabolites)
hAZD9291 Alone (Period 1)AZD9291 + Rifampicin (Period 2)AZD9291 Alone (Period 3)
AZD9291 tss,max4.97 (2.88 to 9.88)5.88 (3.00 to 10.00)6.00 (3.17 to 23.92)
AZ5104 tss,max6.00 (0.00 to 24.00)6.03 (3.00 to 11.43)6.00 (0.00 to 24.00)
AZ7550 tss,max6.14 (2.88 to 24.92)7.95 (4.00 to 12.00)7.03 (1.10 to 24.00)
SecondaryAssessment of Tss,Max for Rifampicin

Rate and extent of absorption of rifampicin by assessment of tss,max. AZD9291 dosing in combination with rifampicin (Period 2).

Time frame:
Samples collected on Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Median · h
Assessment of Tss,Max for Rifampicin
hAZD9291 + Rifampicin (Period 2)
Assessment of Tss,Max for Rifampicin2.00 (0.83 to 6.07)
SecondaryAssessment of Css,Min for AZD9291, and AZ5104 and AZ7550 (Metabolites)

Rate and extent of absorption of AZD9291, and AZ5104 and AZ7550 (metabolites) by assessment of minimum plasma concentration at steady state (Css,min). AZD9291 dosing alone and in combination with rifampicin (all periods).

Time frame:
Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · nM
Assessment of Css,Min for AZD9291, and AZ5104 and AZ7550 (Metabolites)
nMAZD9291 Alone (Period 1)AZD9291 + Rifampicin (Period 2)AZD9291 Alone (Period 3)
AZD9291 Css,min354.7 ± 52.450.56 ± 47.9326.9 ± 41.1
AZ5104 Css,min41.80 ± 62.15.816 ± 51.635.37 ± 51.4
AZ7550 Css,min37.99 ± 44.044.89 ± 26.937.68 ± 35.4
SecondaryAssessment of Css,Min for Rifampicin

Rate and extent of absorption of rifampicin by assessment of minimum plasma concentration at steady state (Css,min). AZD9291 dosing in combination with rifampicin (Period 2).

Time frame:
Samples collected on Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · ng/mL
Assessment of Css,Min for Rifampicin
ng/mLAZD9291 + Rifampicin (Period 2)
Assessment of Css,Min for RifampicinNA ± NA
SecondaryAssessment of CLss/F for AZD9291

Rate and extent of absorption of AZD9291 by assessment of the apparent plasma clearance following oral administration and multiple dosing (CLss/F). AZD9291 dosing alone and in combination with rifampicin (all periods).

Time frame:
Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · Litre per hour (L/h)
Assessment of CLss/F for AZD9291
Litre per hour (L/h)AZD9291 Alone (Period 1)AZD9291 + Rifampicin (Period 2)AZD9291 Alone (Period 3)
Assessment of CLss/F for AZD929114.74 ± 44.273.07 ± 43.815.92 ± 36.7
SecondaryAssessment of CLss/F for Rifampicin

Rate and extent of absorption of rifampicin by assessment of CLss/F. AZD9291 dosing in combination with rifampicin (Period 2).

Time frame:
Samples collected on Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · L/h
Assessment of CLss/F for Rifampicin
L/hAZD9291 + Rifampicin (Period 2)
Assessment of CLss/F for Rifampicin10.23 ± 36.7
SecondaryAssessment of the Metabolic Ratios of Css,Max for AZ5104 and AZ7550 (MRCss,Max)

Assessment of the metabolite to parent ratio (calculated as AZ5104 to AZD9291 and AZ7550 to AZD9291) for Css,max (MRCss,max). AZD9291 dosing alone and in combination with rifampicin (all periods).

Time frame:
Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · Ratio
Assessment of the Metabolic Ratios of Css,Max for AZ5104 and AZ7550 (MRCss,Max)
RatioAZD9291 Alone (Period 1)AZD9291 + Rifampicin (Period 2)AZD9291 Alone (Period 3)
AZ5104 Css,max / AZD9291 Css,max0.1046 ± 31.00.08327 ± 27.40.09544 ± 27.4
AZ7550 Css,max / AZD9291 Css,max0.09276 ± 49.30.4960 ± 33.10.1002 ± 38.1
SecondaryAssessment of the Metabolic Ratios of AUCtau for AZ5104 and AZ7550 (MRAUCtau)

Assessment of the metabolite to parent ratio (calculated as AZ5104 to AZD9291 and AZ7550 to AZD9291) for AUCtau (MRAUCtau). AZD9291 dosing alone and in combination with rifampicin (all periods).

Time frame:
Samples collected on Day 28 and 77 (following AZD9291 alone) and Day 49 (following AZD9291 and rifampicin) at pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose in Part A.
Reported as:
Geometric mean · Ratio
Assessment of the Metabolic Ratios of AUCtau for AZ5104 and AZ7550 (MRAUCtau)
RatioAZD9291 Alone (Period 1)AZD9291 + Rifampicin (Period 2)AZD9291 Alone (Period 3)
AZ5104 AUCtau / AZD9291 AUCtau0.1109 ± 29.00.09595 ± 23.60.1023 ± 28.5
AZ7550 AUCtau / AZD9291 AUCtau0.1019 ± 52.30.6459 ± 28.20.1104 ± 38.8

Adverse events

Collected over Approximately 3 months for Part A; up to approximately 14 months for Part B and approximately 17 months for Overall (Parts A and B combined).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall—11/41 (26.8%)40/41 (97.6%)
Part A—7/41 (17.1%)39/41 (95.1%)
Part B—6/34 (17.6%)34/34 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventOverallPart APart B
InfluenzaInfections and infestations2/411/411/34
Atrial fibrillationCardiac disorders1/410/411/34
IleusGastrointestinal disorders1/410/411/34
Hepatitis BInfections and infestations1/410/411/34
PneumoniaInfections and infestations1/410/411/34
Pulmonary sepsisInfections and infestations1/410/411/34
Thrombotic strokeNervous system disorders1/410/411/34
Cardiac failure congestiveCardiac disorders1/411/410/34
MalaiseGeneral disorders1/411/410/34
Femur fractureInjury, poisoning and procedural complications1/411/410/34
Most frequent other events
Showing 10 of 57
Most frequent other events
EventOverallPart APart B
DiarrhoeaGastrointestinal disorders22/4114/4114/34
Decreased appetiteMetabolism and nutrition disorders19/416/4113/34
Dry skinSkin and subcutaneous tissue disorders17/4110/4112/34
NauseaGastrointestinal disorders13/418/419/34
FatigueGeneral disorders13/418/415/34
VomitingGastrointestinal disorders11/415/417/34
Back painMusculoskeletal and connective tissue disorders11/416/415/34
StomatitisGastrointestinal disorders10/416/416/34
CoughRespiratory, thoracic and mediastinal disorders10/417/414/34
Musculoskeletal painMusculoskeletal and connective tissue disorders9/414/415/34

Baseline characteristics

All patients in the safety analysis set who received at least one dose of AZD9291 (n = 41) were included in the baseline analysis.

Age, Continuous
Age, Continuous(years)AZD9291 and Rifampicin (Part A); AZD9291 Alone (Part B)
Mean62.5 ± 11.74
Sex: Female, Male
Sex: Female, Male(Participants)AZD9291 and Rifampicin (Part A); AZD9291 Alone (Part B)
Female32
Male9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AZD9291 and Rifampicin (Part A); AZD9291 Alone (Part B)
American Indian or Alaska Native0
Asian15
Native Hawaiian or Other Pacific Islander0
Black or African American2
White24
More than one race0
Unknown or Not Reported0
08

Study locations

18 sites
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Seongnam-si, 13620, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Amsterdam, 1066 CX, Netherlands
  • Research Site
    Maastricht, 6229 HX, Netherlands
  • Research Site
    Barcelona, 08041, Spain
  • Research Site
    L'Hospitalet de Llobregat, 08908, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Sevilla, 41013, Spain
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 112, Taiwan
  • Research Site
    Cardiff, CF14 2TL, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeno J, Dingemans AC, Kim HR, Kim JH, Krebs MG, Chih-Hsin Yang J, Bui K, Weilert D, Harvey RD. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol. 2018 Jun;84(6):1156-1169. doi: 10.1111/bcp.13534. Epub 2018 Mar 23. PubMed 29381826 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Jul 2015, 7 months.

Results were first posted in Sep 2016, 1 year 2 months after primary completion.

Of 473 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 7 months is below that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2014
First posted
Jul 22, 2014
StartActual
Dec 4, 2014
Primary completionActual
Jul 9, 2015
CompletionActual
May 26, 2021
Results first posted
Sep 28, 2016
Last update
Jul 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02197247
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 22, 2014
Start date
Dec 4, 2014
Primary completion
Jul 9, 2015
Completion
May 26, 2021
Results posted
Sep 28, 2016
Last update
Jul 12, 2021

Study contacts

Serban Ghiorghiu, MSD
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion